Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Aadi Biosciences Inc (AADI)

Aadi Biosciences Inc (AADI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 52,005
  • Shares Outstanding, K 24,647
  • Annual Sales, $ 24,350 K
  • Annual Income, $ -65,770 K
  • EBIT $ -66 M
  • EBITDA $ -69 M
  • 60-Month Beta 0.71
  • Price/Sales 2.20
  • Price/Cash Flow N/A
  • Price/Book 0.78

Options Overview Details

View History
  • Implied Volatility 180.24% ( +55.91%)
  • Historical Volatility 39.36%
  • IV Percentile 68%
  • IV Rank 24.08%
  • IV High 663.09% on 07/19/24
  • IV Low 27.07% on 08/22/24
  • Put/Call Vol Ratio 0.01
  • Today's Volume 173
  • Volume Avg (30-Day) 36
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 716
  • Open Int (30-Day) 662

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.22
  • Number of Estimates 3
  • High Estimate -0.17
  • Low Estimate -0.28
  • Prior Year -0.60
  • Growth Rate Est. (year over year) +63.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.90 +12.86%
on 10/23/24
2.40 -10.42%
on 11/12/24
+0.04 (+1.90%)
since 10/18/24
3-Month
1.40 +53.57%
on 08/21/24
2.40 -10.42%
on 11/12/24
+0.68 (+46.26%)
since 08/16/24
52-Week
1.21 +77.69%
on 08/08/24
5.70 -62.28%
on 11/29/23
-2.56 (-54.35%)
since 11/17/23

Most Recent Stories

More News
Aadi Bioscience Announces Poster Presentations on Nab-Sirolimus at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting

/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients...

AADI : 2.15 (+1.90%)
Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients...

AADI : 2.15 (+1.90%)
Aadi Bioscience Announces Poster Presentations at the North American Neuroendocrine Tumor Society (NANETS) 2023 Multidisciplinary NET Medical Symposium

/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients...

AADI : 2.15 (+1.90%)
Aadi Bioscience Grants New CEO Dave Lennon, Ph.D. Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients...

AADI : 2.15 (+1.90%)
Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients...

AADI : 2.15 (+1.90%)
Aadi Bioscience Announces Financial Results for the Second Quarter 2023 and Provides Corporate Update

/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically...

AADI : 2.15 (+1.90%)
Aadi Bioscience to Report Second Quarter 2023 Results and Operational Update

/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision...

AADI : 2.15 (+1.90%)
Aadi Bioscience Announces Presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision...

AADI : 2.15 (+1.90%)
Aadi Bioscience Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial

/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically...

AADI : 2.15 (+1.90%)
Aadi Bioscience Announces Multiple Presentations on nab-Sirolimus at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision...

AADI : 2.15 (+1.90%)

Business Summary

Aadi Bioscience Inc. is a clinical-stage biopharmaceutical company. It focuses on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes. Aadi Bioscience Inc., formerly known as Aerpio Pharmaceuticals Inc., is based in LOS ANGELES.

See More

Key Turning Points

3rd Resistance Point 2.21
2nd Resistance Point 2.20
1st Resistance Point 2.17
Last Price 2.15
1st Support Level 2.13
2nd Support Level 2.12
3rd Support Level 2.09

See More

52-Week High 5.70
Fibonacci 61.8% 3.98
Fibonacci 50% 3.45
Fibonacci 38.2% 2.93
Last Price 2.15
52-Week Low 1.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar